ABLYNX (D)

Ablynx specializes in the research and development of nanobodies (therapeutic proteins made from natural antibody fragments) intended to improve treatments for inflammatory diseases, thrombosis, cancer, and Alzheimer's disease. Net sales break down by type of income as follows:
- revenues from partnership agreements (94.6%);
- subsidies (5.4%).